These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

900 related articles for article (PubMed ID: 27165836)

  • 1. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.
    Vaziri ND
    Kidney Int; 2016 Jul; 90(1):41-52. PubMed ID: 27165836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
    Vaziri ND; Liang KH
    Circulation; 2004 Jul; 110(4):419-25. PubMed ID: 15262831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.
    Agrawal S; Zaritsky JJ; Fornoni A; Smoyer WE
    Nat Rev Nephrol; 2018 Jan; 14(1):57-70. PubMed ID: 29176657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
    Vaziri ND; Liang K
    Am J Nephrol; 2004; 24(6):606-13. PubMed ID: 15583480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome.
    Hu P; Lu L; Hu B; Du PF
    Scand J Clin Lab Invest; 2009; 69(6):680-6. PubMed ID: 19468931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol metabolism in glomerular cells: effect of lipoproteins from nephrotic patients.
    Wanner C; Krämer-Guth A; Nauck M; Quaschning T; Pavenstädt H; Schollmeyer P
    Miner Electrolyte Metab; 1996; 22(1-3):39-46. PubMed ID: 8676822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis.
    Vaziri ND; Sato T; Liang K
    Kidney Int; 2003 May; 63(5):1756-63. PubMed ID: 12675851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lipoproteins, apolipoproteins, lipoprotein lipase, hepatic triglyceride lipase and lecithin cholesterol acyltransferase in patients with nephrotic syndrome].
    Breier C; Lisch HJ; Drexel H; Braunsteiner H
    Schweiz Med Wochenschr; 1983 Jun; 113(25):909-13. PubMed ID: 6612272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotic syndrome causes upregulation of HDL endocytic receptor and PDZK-1-dependent downregulation of HDL docking receptor.
    Vaziri ND; Gollapudi P; Han S; Farahmand G; Yuan J; Rahimi A; Moradi H
    Nephrol Dial Transplant; 2011 Oct; 26(10):3118-23. PubMed ID: 21459782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyslipidemia and nephrotic syndrome: recent advances.
    Kronenberg F
    J Ren Nutr; 2005 Apr; 15(2):195-203. PubMed ID: 15827892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome.
    Joven J; Villabona C; Vilella E; Masana L; Albertí R; Vallés M
    N Engl J Med; 1990 Aug; 323(9):579-84. PubMed ID: 2381443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome.
    Stenvinkel P; Berglund L; Ericsson S; Alvestrand A; Angelin B; Eriksson M
    Eur J Clin Invest; 1997 Feb; 27(2):169-77. PubMed ID: 9061312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor-mediated uptake of IDL and LDL from nephrotic patients by glomerular epithelial cells.
    Krämer A; Nauck M; Pavenstädt H; Schwedler S; Wieland H; Schollmeyer P; Wanner C
    Kidney Int; 1993 Dec; 44(6):1341-51. PubMed ID: 8301935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in physiological lipoprotein metabolism.
    Ramasamy I
    Clin Chem Lab Med; 2014 Dec; 52(12):1695-727. PubMed ID: 23940067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions.
    Vaziri ND; Liang K; Azad H
    J Pharmacol Exp Ther; 2000 Aug; 294(2):778-83. PubMed ID: 10900260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristics of lipoprotein metabolism impairments in nephrotic syndrome].
    Titov VN; Tvorogova MG; Levitova EN; Krylova EA
    Vopr Med Khim; 1983; 29(2):17-23. PubMed ID: 6858031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein metabolism in nephrotic syndrome in childhood.
    Oetliker OH; Mordasini R; Lütschg J; Riesen W
    Pediatr Res; 1980 Jan; 14(1):64-6. PubMed ID: 7360522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.
    Vaziri ND
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F262-72. PubMed ID: 16403839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein distribution and composition in the human nephrotic syndrome.
    Muls E; Rosseneu M; Daneels R; Schurgers M; Boelaert J
    Atherosclerosis; 1985 Feb; 54(2):225-37. PubMed ID: 3986019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.